The	O
Prevalence	O
and	O
Clinical	O
Relevance	O
of	O
acetylsalicylic	B:C0004057
acid	I:C0004057
Nonresponse	O
After	O
Cardiac	O
Surgery	I:C0018821
.	O

The	O
Prevalence	O
and	O
Clinical	O
Relevance	O
of	O
acetylsalicylic	O
acid	I:C0004057
Nonresponse	B:C4282382
After	O
Cardiac	O
Surgery	I:C0018821
.	O

The	O
Prevalence	O
and	O
Clinical	O
Relevance	O
of	O
acetylsalicylic	O
acid	I:C0004057
Nonresponse	O
After	O
Cardiac	B:C0018821
Surgery	I:C0018821
.	O

We	O
aimed	O
to	O
identify	O
the	O
prevalence	O
of	O
acetylsalicylic	B:C0004057
acid	I:C0004057
(	O
acetylsalicylic	O
acid	I:C0004057
)	O
nonresponse	O
in	O
patients	O
after	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
(	I:C0010055
CABG	I:C0010055
)	I:C0010055
surgery	I:C0010055
and	O
the	O
possible	O
consequences	O
for	O
the	O
rate	O
of	O
major	O
cardiovascular	O
events	I:C1320716
.	O

We	O
aimed	O
to	O
identify	O
the	O
prevalence	O
of	O
acetylsalicylic	O
acid	I:C0004057
(	O
acetylsalicylic	B:C0004057
acid	I:C0004057
)	O
nonresponse	O
in	O
patients	O
after	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
(	I:C0010055
CABG	I:C0010055
)	I:C0010055
surgery	I:C0010055
and	O
the	O
possible	O
consequences	O
for	O
the	O
rate	O
of	O
major	O
cardiovascular	O
events	I:C1320716
.	O

We	O
aimed	O
to	O
identify	O
the	O
prevalence	O
of	O
acetylsalicylic	O
acid	I:C0004057
(	O
acetylsalicylic	O
acid	I:C0004057
)	O
nonresponse	B:C4282382
in	O
patients	O
after	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
(	I:C0010055
CABG	I:C0010055
)	I:C0010055
surgery	I:C0010055
and	O
the	O
possible	O
consequences	O
for	O
the	O
rate	O
of	O
major	O
cardiovascular	O
events	I:C1320716
.	O

We	O
aimed	O
to	O
identify	O
the	O
prevalence	O
of	O
acetylsalicylic	O
acid	I:C0004057
(	O
acetylsalicylic	O
acid	I:C0004057
)	O
nonresponse	O
in	O
patients	O
after	O
coronary	B:C0010055
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
(	I:C0010055
CABG	I:C0010055
)	I:C0010055
surgery	I:C0010055
and	O
the	O
possible	O
consequences	O
for	O
the	O
rate	O
of	O
major	O
cardiovascular	O
events	I:C1320716
.	O

We	O
aimed	O
to	O
identify	O
the	O
prevalence	O
of	O
acetylsalicylic	O
acid	I:C0004057
(	O
acetylsalicylic	O
acid	I:C0004057
)	O
nonresponse	O
in	O
patients	O
after	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
(	I:C0010055
CABG	I:C0010055
)	I:C0010055
surgery	I:C0010055
and	O
the	O
possible	O
consequences	O
for	O
the	O
rate	O
of	O
major	O
cardiovascular	B:C1320716
events	I:C1320716
.	O

This	O
prospective	B:C0033522
,	O
observational	O
,	O
bicentric	O
cohort	O
study	O
was	O
conducted	O
in	O
two	O
German	O
University	I:C0019994
hospitals	I:C0019994
.	O

This	O
prospective	O
,	O
observational	B:C1518527
,	O
bicentric	O
cohort	O
study	O
was	O
conducted	O
in	O
two	O
German	O
University	I:C0019994
hospitals	I:C0019994
.	O

This	O
prospective	O
,	O
observational	O
,	O
bicentric	O
cohort	O
study	O
was	O
conducted	O
in	O
two	O
German	B:C0019994
University	I:C0019994
hospitals	I:C0019994
.	O

A	O
total	O
of	O
400	O
patients	O
(	O
200	O
in	O
each	O
study	O
center	O
)	O
undergoing	O
elective	B:C0206058
CABG	O
surgery	I:C0010055
were	O
enrolled	O
after	O
written	O
informed	O
consent	O
.	O

A	O
total	O
of	O
400	O
patients	O
(	O
200	O
in	O
each	O
study	O
center	O
)	O
undergoing	O
elective	O
CABG	B:C0010055
surgery	I:C0010055
were	O
enrolled	O
after	O
written	O
informed	O
consent	O
.	O

Platelet	B:C1254881
function	I:C1254881
was	O
analyzed	O
on	O
day	O
3	O
(	O
d3	O
)	O
and	O
day	O
5	O
(	O
d5	O
)	O
postoperatively	O
following	O
stimulation	O
with	O
arachidonic	O
acid	I:C0003695
(	O
ASPItest	O
)	O
and	O
with	O
thrombin	O
receptor	I:C0219419
-	I:C0219419
activating	I:C0219419
peptide	I:C0219419
6	I:C0219419
(	O
TRAPtest	O
)	O
using	O
multiple	O
electrode	I:C0032184
aggregometry	I:C0032184
(	O
Multiplate	O
)	O
.	O

Platelet	O
function	I:C1254881
was	O
analyzed	O
on	O
day	O
3	O
(	O
d3	O
)	O
and	O
day	O
5	O
(	O
d5	O
)	O
postoperatively	O
following	O
stimulation	O
with	O
arachidonic	B:C0003695
acid	I:C0003695
(	O
ASPItest	O
)	O
and	O
with	O
thrombin	O
receptor	I:C0219419
-	I:C0219419
activating	I:C0219419
peptide	I:C0219419
6	I:C0219419
(	O
TRAPtest	O
)	O
using	O
multiple	O
electrode	I:C0032184
aggregometry	I:C0032184
(	O
Multiplate	O
)	O
.	O

Platelet	O
function	I:C1254881
was	O
analyzed	O
on	O
day	O
3	O
(	O
d3	O
)	O
and	O
day	O
5	O
(	O
d5	O
)	O
postoperatively	O
following	O
stimulation	O
with	O
arachidonic	O
acid	I:C0003695
(	O
ASPItest	B:C0032184
)	O
and	O
with	O
thrombin	O
receptor	I:C0219419
-	I:C0219419
activating	I:C0219419
peptide	I:C0219419
6	I:C0219419
(	O
TRAPtest	O
)	O
using	O
multiple	O
electrode	I:C0032184
aggregometry	I:C0032184
(	O
Multiplate	O
)	O
.	O

Platelet	O
function	I:C1254881
was	O
analyzed	O
on	O
day	O
3	O
(	O
d3	O
)	O
and	O
day	O
5	O
(	O
d5	O
)	O
postoperatively	O
following	O
stimulation	O
with	O
arachidonic	O
acid	I:C0003695
(	O
ASPItest	O
)	O
and	O
with	O
thrombin	B:C0219419
receptor	I:C0219419
-	I:C0219419
activating	I:C0219419
peptide	I:C0219419
6	I:C0219419
(	O
TRAPtest	O
)	O
using	O
multiple	O
electrode	I:C0032184
aggregometry	I:C0032184
(	O
Multiplate	O
)	O
.	O

Platelet	O
function	I:C1254881
was	O
analyzed	O
on	O
day	O
3	O
(	O
d3	O
)	O
and	O
day	O
5	O
(	O
d5	O
)	O
postoperatively	O
following	O
stimulation	O
with	O
arachidonic	O
acid	I:C0003695
(	O
ASPItest	O
)	O
and	O
with	O
thrombin	O
receptor	I:C0219419
-	I:C0219419
activating	I:C0219419
peptide	I:C0219419
6	I:C0219419
(	O
TRAPtest	B:C0032184
)	O
using	O
multiple	O
electrode	I:C0032184
aggregometry	I:C0032184
(	O
Multiplate	O
)	O
.	O

Platelet	O
function	I:C1254881
was	O
analyzed	O
on	O
day	O
3	O
(	O
d3	O
)	O
and	O
day	O
5	O
(	O
d5	O
)	O
postoperatively	O
following	O
stimulation	O
with	O
arachidonic	O
acid	I:C0003695
(	O
ASPItest	O
)	O
and	O
with	O
thrombin	O
receptor	I:C0219419
-	I:C0219419
activating	I:C0219419
peptide	I:C0219419
6	I:C0219419
(	O
TRAPtest	O
)	O
using	O
multiple	B:C0032184
electrode	I:C0032184
aggregometry	I:C0032184
(	O
Multiplate	O
)	O
.	O

Platelet	O
function	I:C1254881
was	O
analyzed	O
on	O
day	O
3	O
(	O
d3	O
)	O
and	O
day	O
5	O
(	O
d5	O
)	O
postoperatively	O
following	O
stimulation	O
with	O
arachidonic	O
acid	I:C0003695
(	O
ASPItest	O
)	O
and	O
with	O
thrombin	O
receptor	I:C0219419
-	I:C0219419
activating	I:C0219419
peptide	I:C0219419
6	I:C0219419
(	O
TRAPtest	O
)	O
using	O
multiple	O
electrode	I:C0032184
aggregometry	I:C0032184
(	O
Multiplate	B:C0032184
)	O
.	O

Individuals	O
with	O
an	O
ASPItest	B:C0032184
≥	O
40	O
AU·min	O
were	O
categorized	O
as	O
acetylsalicylic	O
acid	I:C0004057
nonresponders	O
.	O

Individuals	O
with	O
an	O
ASPItest	O
≥	O
40	O
AU·min	O
were	O
categorized	O
as	O
acetylsalicylic	B:C0004057
acid	I:C0004057
nonresponders	O
.	O

Individuals	O
with	O
an	O
ASPItest	O
≥	O
40	O
AU·min	O
were	O
categorized	O
as	O
acetylsalicylic	O
acid	I:C0004057
nonresponders	B:C0919875
.	O

A	O
1	O
-	O
year	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
recorded	O
the	O
combined	O
end	O
point	O
of	O
cardiovascular	O
events	I:C1320716
,	O
hospital	O
admissions	I:C0184666
,	O
or	O
deaths	O
related	O
to	O
cardiovascular	O
disease	I:C0007222
.	O

A	O
1	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
recorded	O
the	O
combined	O
end	O
point	O
of	O
cardiovascular	B:C1320716
events	I:C1320716
,	O
hospital	O
admissions	I:C0184666
,	O
or	O
deaths	O
related	O
to	O
cardiovascular	O
disease	I:C0007222
.	O

A	O
1	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
recorded	O
the	O
combined	O
end	O
point	O
of	O
cardiovascular	O
events	I:C1320716
,	O
hospital	B:C0184666
admissions	I:C0184666
,	O
or	O
deaths	O
related	O
to	O
cardiovascular	O
disease	I:C0007222
.	O

A	O
1	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
recorded	O
the	O
combined	O
end	O
point	O
of	O
cardiovascular	O
events	I:C1320716
,	O
hospital	O
admissions	I:C0184666
,	O
or	O
deaths	B:C1306577
related	O
to	O
cardiovascular	O
disease	I:C0007222
.	O

A	O
1	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
recorded	O
the	O
combined	O
end	O
point	O
of	O
cardiovascular	O
events	I:C1320716
,	O
hospital	O
admissions	I:C0184666
,	O
or	O
deaths	O
related	O
to	O
cardiovascular	B:C0007222
disease	I:C0007222
.	O

The	O
prevalence	O
of	O
acetylsalicylic	B:C0004057
acid	I:C0004057
nonresponse	O
was	O
51.5	O
%	O
on	O
d3	O
,	O
and	O
it	O
significantly	O
increased	O
to	O
71.3	O
%	O
on	O
d5	O
(	O
P	O
=	O
.0049	O
)	O
.	O

The	O
prevalence	O
of	O
acetylsalicylic	O
acid	I:C0004057
nonresponse	B:C4282382
was	O
51.5	O
%	O
on	O
d3	O
,	O
and	O
it	O
significantly	O
increased	O
to	O
71.3	O
%	O
on	O
d5	O
(	O
P	O
=	O
.0049	O
)	O
.	O

The	O
area	O
under	O
the	O
aggregation	B:C3828533
curve	I:C3828533
in	O
the	O
TRAPtest	O
(	O
P	O
<	O
.0001	O
)	O
,	O
the	O
platelet	O
count	I:C0032181
on	O
d5	O
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
the	O
cardiopulmonary	O
bypass	I:C0429123
time	I:C0429123
(	O
P	O
=	O
.01	O
)	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
acetylsalicylic	O
acid	I:C0004057
nonresponse	O
.	O

The	O
area	O
under	O
the	O
aggregation	O
curve	I:C3828533
in	O
the	O
TRAPtest	B:C0032184
(	O
P	O
<	O
.0001	O
)	O
,	O
the	O
platelet	O
count	I:C0032181
on	O
d5	O
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
the	O
cardiopulmonary	O
bypass	I:C0429123
time	I:C0429123
(	O
P	O
=	O
.01	O
)	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
acetylsalicylic	O
acid	I:C0004057
nonresponse	O
.	O

The	O
area	O
under	O
the	O
aggregation	O
curve	I:C3828533
in	O
the	O
TRAPtest	O
(	O
P	O
<	O
.0001	O
)	O
,	O
the	O
platelet	B:C0032181
count	I:C0032181
on	O
d5	O
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
the	O
cardiopulmonary	O
bypass	I:C0429123
time	I:C0429123
(	O
P	O
=	O
.01	O
)	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
acetylsalicylic	O
acid	I:C0004057
nonresponse	O
.	O

The	O
area	O
under	O
the	O
aggregation	O
curve	I:C3828533
in	O
the	O
TRAPtest	O
(	O
P	O
<	O
.0001	O
)	O
,	O
the	O
platelet	O
count	I:C0032181
on	O
d5	O
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
the	O
cardiopulmonary	B:C0429123
bypass	I:C0429123
time	I:C0429123
(	O
P	O
=	O
.01	O
)	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
acetylsalicylic	O
acid	I:C0004057
nonresponse	O
.	O

The	O
area	O
under	O
the	O
aggregation	O
curve	I:C3828533
in	O
the	O
TRAPtest	O
(	O
P	O
<	O
.0001	O
)	O
,	O
the	O
platelet	O
count	I:C0032181
on	O
d5	O
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
the	O
cardiopulmonary	O
bypass	I:C0429123
time	I:C0429123
(	O
P	O
=	O
.01	O
)	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
acetylsalicylic	B:C0004057
acid	I:C0004057
nonresponse	O
.	O

The	O
area	O
under	O
the	O
aggregation	O
curve	I:C3828533
in	O
the	O
TRAPtest	O
(	O
P	O
<	O
.0001	O
)	O
,	O
the	O
platelet	O
count	I:C0032181
on	O
d5	O
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
the	O
cardiopulmonary	O
bypass	I:C0429123
time	I:C0429123
(	O
P	O
=	O
.01	O
)	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
acetylsalicylic	O
acid	I:C0004057
nonresponse	B:C4282382
.	O

A	O
1	O
-	O
year	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
recorded	O
54	O
events	O
fulfilling	O
criteria	O
for	O
the	O
combined	O
end	O
point	O
with	O
no	O
difference	O
between	O
acetylsalicylic	O
acid	I:C0004057
responders	O
and	O
nonresponders	O
.	O

A	O
1	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
recorded	O
54	O
events	O
fulfilling	O
criteria	O
for	O
the	O
combined	O
end	O
point	O
with	O
no	O
difference	O
between	O
acetylsalicylic	B:C0004057
acid	I:C0004057
responders	O
and	O
nonresponders	O
.	O

A	O
1	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
recorded	O
54	O
events	O
fulfilling	O
criteria	O
for	O
the	O
combined	O
end	O
point	O
with	O
no	O
difference	O
between	O
acetylsalicylic	O
acid	I:C0004057
responders	B:C0919876
and	O
nonresponders	O
.	O

A	O
1	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
recorded	O
54	O
events	O
fulfilling	O
criteria	O
for	O
the	O
combined	O
end	O
point	O
with	O
no	O
difference	O
between	O
acetylsalicylic	O
acid	I:C0004057
responders	O
and	O
nonresponders	B:C0919875
.	O

This	O
study	B:C0008972
indicates	O
a	O
high	O
incidence	O
of	O
perioperative	O
acetylsalicylic	O
acid	I:C0004057
nonresponse	O
in	O
patients	O
following	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
.	O

This	O
study	O
indicates	O
a	O
high	O
incidence	O
of	O
perioperative	O
acetylsalicylic	B:C0004057
acid	I:C0004057
nonresponse	O
in	O
patients	O
following	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
.	O

This	O
study	O
indicates	O
a	O
high	O
incidence	O
of	O
perioperative	O
acetylsalicylic	O
acid	I:C0004057
nonresponse	B:C4282382
in	O
patients	O
following	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
.	O

This	O
study	O
indicates	O
a	O
high	O
incidence	O
of	O
perioperative	O
acetylsalicylic	O
acid	I:C0004057
nonresponse	O
in	O
patients	O
following	O
coronary	B:C0010055
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
.	O

No	O
effect	O
on	O
the	O
incidence	O
of	O
cardiovascular	B:C1320716
events	I:C1320716
was	O
recorded	O
in	O
the	O
1	O
-	O
year	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

No	O
effect	O
on	O
the	O
incidence	O
of	O
cardiovascular	O
events	I:C1320716
was	O
recorded	O
in	O
the	O
1	O
-	O
year	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
.	O

Therefore	O
,	O
a	O
randomized	B:C0206034
dosage	I:C0206034
adjustment	I:C0206034
trial	I:C0206034
should	O
elucidate	O
whether	O
a	O
tailored	O
acetylsalicylic	O
acid	I:C0004057
treatment	O
after	O
CABG	O
surgery	I:C0010055
represents	O
a	O
useful	O
concept	O
.	O

Therefore	O
,	O
a	O
randomized	O
dosage	I:C0206034
adjustment	I:C0206034
trial	I:C0206034
should	O
elucidate	O
whether	O
a	O
tailored	O
acetylsalicylic	B:C0004057
acid	I:C0004057
treatment	O
after	O
CABG	O
surgery	I:C0010055
represents	O
a	O
useful	O
concept	O
.	O

Therefore	O
,	O
a	O
randomized	O
dosage	I:C0206034
adjustment	I:C0206034
trial	I:C0206034
should	O
elucidate	O
whether	O
a	O
tailored	O
acetylsalicylic	O
acid	I:C0004057
treatment	B:C1533734
after	O
CABG	O
surgery	I:C0010055
represents	O
a	O
useful	O
concept	O
.	O

Therefore	O
,	O
a	O
randomized	O
dosage	I:C0206034
adjustment	I:C0206034
trial	I:C0206034
should	O
elucidate	O
whether	O
a	O
tailored	O
acetylsalicylic	O
acid	I:C0004057
treatment	O
after	O
CABG	B:C0010055
surgery	I:C0010055
represents	O
a	O
useful	O
concept	O
.	O

